Nautilus Biotechnology, Inc. (NAUT) Institutional Ownership

Ownership Summary

The institutional landscape for Nautilus Biotechnology, Inc. (NASDAQ:NAUT) includes 65 filers as of the latest reporting cycle ending December 2025.

• These investors collectively held 47.1% of the company's total shares outstanding in December 2025, up from 46.9% in September 2025.
• In percentage terms, this reflects as a holdings change of 2.14% quarter on quarter, and a decrease of 27.78% year over year.
• During the quarter, 29 institutions bought more Nautilus Biotechnology shares, 12 sold shares, and 24 of the 65 total investors held their position steady.
• The aggregate institutional position in Nautilus Biotechnology now stands at 58.11Mn shares as of December 2025, after investors increased their holdings (up by 1.22Mn shares quarter on quarter which is down 5.76Mn shares year over year).
• The top institutional stake in Nautilus Biotechnology as of December 31, 2025 belongs to a16z Capital Management, L.L.C., which owns 17.65Mn shares, or 14.31% of the company.
• Among the most significant buyers of Nautilus Biotechnology during December 2025 were SENTINEL TRUST CO LBA (750.00K), ACADIAN ASSET MANAGEMENT LLC (368.71K), GOLDMAN SACHS GROUP INC (179.72K), VANGUARD GROUP INC (166.39K), MARSHALL WACE, LLP (117.06K).
• Leading sellers of Nautilus Biotechnology stock in December 2025 included RENAISSANCE TECHNOLOGIES LLC (747.76K), GSA CAPITAL PARTNERS LLP (135.15K), Squarepoint Ops LLC (120.51K), DIMENSIONAL FUND ADVISORS LP (79.24K), BlackRock, Inc. (12.01K).
• The top 10 institutional holders of Nautilus Biotechnology for the quarter ending December 2025 included a16z Capital Management, L.L.C. (17.65Mn), PERCEPTIVE ADVISORS LLC (12.59Mn), Cercano Management LLC (7.17Mn), Madrona Venture Group, LLC (6.02Mn), VANGUARD GROUP INC (2.60Mn), Comprehensive Financial Management LLC (2.21Mn), AMAZON COM INC (1.46Mn), Clarius Group, LLC (1.21Mn), MILLENNIUM MANAGEMENT LLC (1.02Mn), SENTINEL TRUST CO LBA (750.00K).